With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • October 5, 2017New Targeted Alpha Therapy Protocol for Advanced Prostate Cancer
    Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer (mCRPC), but a new treatment protocol reported in the featured article of The Journal of Nuclear Medicine's October issue offers hope.
  • October 5, 2017Novel PET Tracer Identifies Most Bacterial Infections
    Stanford University medical scientists have developed a novel imaging agent that could be used to identify most bacterial infections. The study is the featured basic science article in The Journal of Nuclear Medicine’s October issue.
  • October 3, 2017New Targeted Alpha Therapy Protocol for Advanced Prostate Cancer
    Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. In the featured article of The Journal of Nuclear Medicine’s October issue, German researchers report on a new dosing regimen for actinium-225-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.
  • September 15, 2017New publication calls for greater research and investment in theranostics
    Theranostics is the future of precision medicine, according to The Journal of Nuclear Medicine’s September 2017 supplemental issue.
  • September 15, 2017Novel PET tracer could identify bacterial infections
    Researchers from Stanford University are reporting promising early results in the development of a novel PET radiopharmaceutical designed to identify most bacterial infections. Their findings were published in the October issue of the Journal of Nuclear Medicine.
  • September 14, 2017New Book Available on Abdominal Imaging
    "Abdominal Imaging 2017: Quality, Safety, & Dose Optimization" is the second installment in a series of books dedicated to a single nuclear medicine procedure or imaging category. The book is put out by the SNMMI-TS Publications Committee, and chapters cover imaging rationale, indications, contraindications, patient preparation and education, imaging procedure, processing, interpretation including normal and abnormal results, sensitivity/specificity/accuracy, and artifacts.
  • September 13, 2017Theranostics: Paintball Targeting of Cancer Cells Combined with Precision Therapy
    The Journal of Nuclear Medicine’s September supplement shines a spotlight on theranostics and its increasingly important role in delivering precision medicine. Theranostics refers to the combination of a predictive biomarker, identified through diagnostic imaging using radiolabeled ligands, with precise therapy targeted on the now-marked cancer cells. The cancer cells are destroyed, while healthy cells are unharmed.
  • September 7, 2017Double targeting ligands to identify and treat prostate cancer
    Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects.The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.